Temazepam half-life
Temazepam labeling reports substantial interindividual variation around a roughly nine-hour center.
Every curve begins at 100%. No dose or measured body concentration is assumed.
X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. The shaded band shows the reported half-life range. This is a mathematical visualization, not a personal concentration estimate.
Temazepam: evidence and interpretation notes
The number behind the long tail
Temazepam labeling reports substantial interindividual variation around a roughly nine-hour center. The range belongs beside the line because residual sedation cannot be assigned from the midpoint alone.
A 9-hour input gives this profile one auditable line for Temazepam. The line deliberately stops short of claims about clinical effect, measured concentration, or testing results.
Temazepam may involve residual sedation, active metabolites, age-related differences, and co-medication effects. The curve is a parent-drug simplification, not a next-day impairment or withdrawal model.
What each source contributes
- DailyMed: RESTORIL (TEMAZEPAM) CAPSULE [SPECGX LLC]. This product label adds formulation-specific pharmacokinetic context and does not represent every route or product.
- PubChem: Temazepam. This identity record confirms names and compound identity and does not supply a human half-life.
- Divoll M et al. Effect of age and gender on disposition of temazepam (1981). This human volunteer study adds an 8-to-38-hour elimination range and sex-related variability, showing why the nine-hour center cannot represent every adult.
For Temazepam, the numerical model is tied most closely to DailyMed: RESTORIL (TEMAZEPAM) CAPSULE [SPECGX LLC]. As a product label, it adds formulation-specific pharmacokinetic context; it does not represent every route or product.
Why the range stays visible
The labeled 3.5-to-18.4-hour terminal range is retained beside the rounded nine-hour input for Temazepam. It is not an uncertainty slider or a personalized prediction; the separate volunteer study’s 8-to-38-hour span reinforces that population and method can widen the observed result.
InterpretationReading the curve and its category context
Reading this curve
HalfLifeDB uses 9 h as a representative input for Temazepam. In the simplified model, about 15.7% remains after 24 hours and about 3% remains after five half-lives, or roughly 45 h.
This sits in the same-day range. The chart is useful for seeing the bend of the curve across a day or two, but it should not be treated as a personal clock. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.
benzodiazepine context
Benzodiazepine half-life estimates can be especially sensitive to active metabolites, redistribution, age, liver function, and repeated use.
- A long terminal half-life does not mean effects remain constant for the whole period.
- Shorter-acting entries can still have residual effects after the main subjective effects fade.
- Repeated exposure can create overlap that a single-dose curve does not show.
ComparisonTimeline checkpoints and nearby profiles
Temazepam timeline checkpoints
| Elapsed time | Modeled remaining | Reading note |
|---|---|---|
| 12 h | 39.7% | Meaningful modeled decline, not near-zero |
| 24 h | 15.7% | Long-tail portion of the model |
| 2.0 days | 2.48% | Low modeled remainder, not a clearance guarantee |
| 3.0 days | 0.39% | Low modeled remainder, not a clearance guarantee |
| 5.0 days | 0.01% | Low modeled remainder, not a clearance guarantee |
Nearby profiles by half-life
These entries sit near Temazepam within the benzodiazepine group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.
- Alprazolam (11.2 h)
- Midazolam (2.5 h)
- Lorazepam (14 h)
- Diazepam (30 h)
EvidencePharmacokinetic inputs and source trail
Pharmacokinetics at a glance
| Representative half-life | 9 h |
|---|---|
| Reported range | 3.5 h to 18.4 h |
| Curve type | Normalized, first-order decline |
Selection note: Temazepam labeling reports substantial interindividual variation around a roughly nine-hour center. The range belongs beside the line because residual sedation cannot be assigned from the midpoint alone.
Sources and evidence context
A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.
- Official labeling DailyMed label: RESTORIL (TEMAZEPAM) CAPSULE [SPECGX LLC].Official U.S. product labeling used for formulation and labeled pharmacokinetic context; its statements apply to the described product.
- Identity record PubChem Compound Summary: Temazepam.Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
- Research abstract Divoll M et al. Effect of age and gender on disposition of temazepam (1981).Human volunteer study reporting an 8-to-38-hour elimination range and a longer mean in women than men. It demonstrates variability rather than supplying the nine-hour plotted center.
BoundariesWhat this page cannot answer and where to continue
What this page does not answer
- It does not estimate impairment, intoxication, or fitness to drive.
- It does not predict urine, blood, saliva, or hair test results.
- It does not model repeated exposure, tolerance, withdrawal, or interactions.
- It does not replace clinician, pharmacist, toxicologist, or emergency guidance.
Continue with context
- All substance profiles
- Browse the benzodiazepine group
- Compare this curve
- Clearance and volume of distribution
- Bioavailability, route, and formulation
- Active metabolites and parent compounds
- First-order vs nonlinear kinetics
- Detection windows vs half-life
- Reading labels and source quality
Read the medical disclaimer, methodology, and research standards before using the model for comparison.